388.31
+1.77%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bio Rad Laboratories
From its filings with the US Securities and Exchange Commission
Bio Rad Laboratories is based in Hercules, California and is incorporated in Delaware. Its shares trade on NYSE under the ticker BIO. The SEC classifies its business as laboratory analytical instruments. In the fiscal year to 31 December 2025, it reported revenue of $2.58bn and net income of $759.9m. At that date it held total assets of $10.58bn and shareholders' equity of $7.45bn. By region, UNITED STATES accounted for 39.6%, followed by Europe [Member] at 34.1% and Asia [Member] at 19.9%.
Bio-Rad Laboratories, Inc. (referred to in this report as “Bio-Rad,” “we,” “us,” “the Company,” and “our”) is a multinational life science and clinical diagnostics company that develops, manufactures, and markets a broad portfolio of instruments, systems, reagents, and consumables.
We have direct operations in over 36 countries outside the United States through subsidiaries focused on sales, customer service, and product distribution. In certain locations outside and within these countries, our sales efforts are supplemented by distributors and agents.
Bio-Rad operates in two industry segments designated as Life Science and Clinical Diagnostics. Both segments operate worldwide. Our Life Science segment and our Clinical Diagnostics segment generated approximately 40% and 60%, respectively, of our consolidated net sales for the year ended December 31, 2025. We generated approximately 40% of our consolidated net sales for the year ended December 31, 2025 from the U.S. and approximately 60% from our international locations, with Europe being our largest international region.
Our Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids. These products are utilized in research and biopharmaceutical laboratory environments, as well as in biopharmaceutical manufacturing, quality control processes, food safety testing, and science education applications.
Quoted from its 10-K, filed 13 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 22 May 1981
- Employees
- 7,450
- Website
- bio-rad.com ↗
- Head office
- 1000 ALFRED NOBEL DRIVE, HERCULES, CA, 94547
- Incorporated in
- DE
- Classification
- Laboratory Analytical Instruments
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Norman SchwartzChairman of the Board, Chief Executive Officer, since 1995$8.3m
- Mr. Jonathan DivincenzoPresident, Chief Operating Officer$4.3m
- Mr. Roop LakkarajuChief Financial Officer, Executive Vice President$3.8m
- Ms. Courtney EnloeExecutive Vice President, General Counsel, Secretary
- Ms. Colleen CoreyExecutive Vice President, Global Human Resources
- Mr. James BarryExecutive Vice President, President - Life Science Group
- Mr. Michael CrowleyExecutive Vice President - Global Commercial Operations$2.2m
- Ms. Eva Anette EngelhardtExecutive Vice President, President of Clinical Diagnostics Group$2.2m
- Mr. Sedat EvranExecutive Vice President - Global Supply Chain
- Mr. Rajat MehtaExecutive Vice President - Global Commercial Operations
- Mr. Gregory HinckleyLead Independent Director$339,563
- Ms. Allison SchwartzDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 41
- Environment
- 41
- Social
- 62
- Governance
- 20
- Direct emissions (scope 1)
- 10,563 t
- Energy emissions (scope 2)
- 13,906 t
- Value chain emissions (scope 3)
- 295,930 t
- Women in the workforce
- 44%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bio Rad Laboratories Inc is a leading global provider of life science research and clinical diagnostics products. The company has an extensive product portfolio, ranging from instruments and reagents to software and services, catering to the needs of various scientific and healthcare professionals.
- Bio Rad has a strong brand reputation and is recognized for its high-quality and innovative solutions. This reputation enables the company to attract and retain loyal customers in the highly competitive life sciences industry.
- The company's research and development capabilities are a significant strength, as they allow Bio Rad to constantly introduce new products and technologies to meet changing market demands.
Weaknesses
- Despite its strong market position, Bio Rad faces certain weaknesses. One of these weaknesses is its dependence on a limited number of key customers, which puts the company at risk if any of these customers reduce their purchasing volumes or switch to competitors.
- Another weakness is the company's limited geographic diversification. Bio Rad operates primarily in the United States, making it vulnerable to fluctuations in the domestic market and potentially missing out on international growth opportunities.
Opportunities
- Bio Rad has several opportunities for growth. The increasing global focus on healthcare and research presents opportunities for the company to expand its customer base and enhance market penetration. The growing demand for personalized medicine and genetic testing also offers new avenues for product development and revenue generation.
- Furthermore, strategic partnerships and collaborations with other industry players or academic institutions can provide Bio Rad with access to complementary technologies and expertise, enabling the company to offer more comprehensive solutions to its customers.
Threats
- The highly competitive nature of the life sciences industry poses a significant threat to Bio Rad. The company faces intense competition from both large multinational corporations and smaller specialized companies, which may have competitive advantages in certain niche markets.
- Additionally, regulatory requirements and compliance challenges in the healthcare and life sciences sectors can pose risks and add complexity to Bio Rad's operations. Changes in regulations or failure to comply with existing ones may impact the company's ability to market and sell its products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.